Polyomavirus-associated nephropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:27:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Polyomavirus-associated nephropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Tacrolimus and Drug Combination for Patients with BK Polyomavirus Infection After Kidney Transplantation https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tacrolimus-and-drug-combination-for-patients-with-bk-polyomavirus-infection-after-kidney-transplantation/ Wed, 29 Apr 2026 15:04:38 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tacrolimus-and-drug-combination-for-patients-with-bk-polyomavirus-infection-after-kidney-transplantation/ This clinical trial is focused on studying the safety and effectiveness of different approaches to managing immunosuppressive therapy in patients who have undergone a kidney transplant and are experiencing a condition known as BK Polyomavirus DNAemia. This condition occurs when there is a significant amount of BK virus DNA in the blood, which can be a concern for kidney transplant recipients. The study will compare two groups: one group will continue their current immunosuppressive treatment, while the other group will have their treatment reduced according to standard guidelines. The goal is to see if maintaining the current level of immunosuppression is just as effective as reducing it in terms of how quickly the virus levels decrease in the blood.

The medications involved in this study include Tacrolimus, Azathioprine, Sirolimus, Belatacept, Mycophenolic Acid, Ciclosporin, Everolimus, Mycophenolate Mofetil, and Prednisolone. These medications are commonly used to suppress the immune system and prevent the body from rejecting a transplanted kidney. The study will monitor the time it takes for the virus levels to drop to a safe level, as well as other factors such as kidney function, any episodes of the body rejecting the kidney, and the presence of antibodies that might attack the transplanted organ.

Participants in the study will be randomly assigned to one of the two groups and will be monitored over a period of nine months. The study will track various health indicators, including kidney function and the presence of the virus in the blood, to determine the best approach to managing immunosuppression in these patients. The study aims to provide valuable information on how to best protect kidney transplant recipients from complications related to BK Polyomavirus while maintaining the health of the transplanted kidney.

]]>